What is it about?
In this mixed treatment comparison meta-analysis of 6 independent randomized trials with 783 subjects, both droxidopa and midodrine were associated with significant increases in standing systolic BP compared to placebo with mididrine exerting a significantly greater effect than droxidopa; however only midodrine was associated with a significantly higher risk of supine hypertension events when compared to placebo.
Featured Image
Why is it important?
The greater risk of supine hypertension associated with midodrine suggests caution in prescribing this medication as a first-line therapy.
Perspectives
This article utilizes network meta-analytical techniques to answer questions that will not likely be determined otherwise.
Jack Chen
American University of Health Sciences
Read the Original
This page is a summary of: Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials, Annals of Pharmacotherapy, July 2018, SAGE Publications,
DOI: 10.1177/1060028018786954.
You can read the full text:
Contributors
The following have contributed to this page
